P. Knight

发表

The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities

D. Viskochil, E. Schorry, L. Klesse, 2020, The oncologist.

Explaining the influence of internalized religious identity on health behaviour by the theory of planned behaviour

P. Knight, 2012 .

Neurofibromatosis as a gateway to better treatment for a variety of malignancies

L. Sherman, Annette C. Bakker, S. L. Rosa, 2017, Progress in Neurobiology.

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research

B. Korf, S. Plotkin, N. Ullrich, 2021, Orphanet Journal of Rare Diseases.

Cutaneous neurofibromas in the genomics era: current understanding and open questions

Robert J. Allaway, J. Guinney, Salvatore La Rosa, 2018, British Journal of Cancer.

A high-throughput molecular data resource for cutaneous neurofibromas

S. Levy, H. Weinberg, J. Guinney, 2017, Scientific Data.

Cutaneous neurofibromas in the genomics era: current understanding and open questions

Robert J. Allaway, J. Guinney, Salvatore La Rosa, 2018, British Journal of Cancer.

Phenotypic heterogeneity of neurofibromatosis type 1 in a large international registry

K. Sarin, Shufeng Li, Annette C. Bakker, 2020, JCI insight.

Characterization and utilization of an international neurofibromatosis web-based, patient–entered registry: An observational study

B. Korf, D. Viskochil, R. Holzman, 2017, PloS one.

Current status and recommendations for biomarkers and biobanking in neurofibromatosis

A. Stemmer-Rachamimov, B. Korf, D. Evans, 2016, Neurology.

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis

S. Plotkin, V. Merker, J. Jordan, 2018, BMC Health Services Research.

Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists

S. Plotkin, N. Ullrich, V. Merker, 2021, Orphanet Journal of Rare Diseases.